Testosterone cypionate
- Generic Name
- Testosterone cypionate
- Brand Names
- Depo-testosterone
- Drug Type
- Small Molecule
- Chemical Formula
- C27H40O3
- CAS Number
- 58-20-8
- Unique Ingredient Identifier
- M0XW1UBI14
- Background
Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.
- Indication
Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by id...
- Associated Conditions
- Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism
- Associated Therapies
- -
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT06305598
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06111209
Sipuleucel-T Combined with Bipolar Androgen Therapy in Men with MCRPC
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 26
- Registration Number
- NCT06100705
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-02-14
- Target Recruit Count
- 50
- Registration Number
- NCT06059118
- Locations
- 🇺🇸
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 46
- Registration Number
- NCT06039371
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04895306
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.
- Conditions
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 9
- Registration Number
- NCT04757532
- Locations
- 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Emory University
- Target Recruit Count
- 100
- Registration Number
- NCT04731376
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Latin American Cooperative Oncology Group
- Target Recruit Count
- 51
- Registration Number
- NCT04558866
- Locations
- 🇧🇷
CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas), Rio De Janeiro, Brazil
🇧🇷HMV - Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Hospital Sírio-Libanês SP, São Paulo, Brazil
Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 4
- Registration Number
- NCT04551144
- Locations
- 🇺🇸
Saint Louis Univeristy, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.